Navigation Links
Warnings for Hepatitis B Reactivation in Cancer Patients Welcomed by the American Association for the Study of Liver Diseases
Date:9/30/2013

ALEXANDRIA, Va., Sept. 30, 2013 /PRNewswire/ -- Food and Drug Administration (FDA) announced the requirement of a Boxed Warning for the anti-cancer immunosuppressive drugs Arzerra (ofatumumab) and Rituxan (rituximab). The Boxed Warning is specific to the risk of reactivating hepatitis B virus (HBV) in patients who were previously infected with the virus. Use of these drugs in patients with prior HBV infection can result in severe liver damage if the virus is reactivated.

The American Association for the Study of Liver Diseases represents the hepatology community, which has recognized for more than a decade that treatment of cancer with chemotherapy sometimes results in reactivation of HBV. The risk of HBV reactivation is already described in the Warnings and Precautions section of the labels for both drugs; however, the FDA's monitoring system had continued to detect cases of HBV reactivation with these agents and independently came to appreciate the problem's persistence.

AASLD convened a conference on the subject of HBV reactivation during chemotherapy in March 2013, and representatives of the FDA were present at the meeting and engaged in discussions. Those discussions between AASLD and the FDA were continued through the summer. According to AASLD President-Elect Adrian Di Bisceglie, MD, "AASLD members were recognized as experts and our persistence as an organization in this area helped FDA make up its mind to notify prescribing physicians of this problem."

The FDA also released new recommendations to decrease the risk of HBV reactivation when these drugs are used. Addressing this risk of hepatitis B reactivation, the full FDA communication states: "The revised labels will include additional recommendations for screening, monitoring, and managing these patients on these drugs to decrease this risk."

The Warnings and Precautions section is being revised for each drug to express new recommendations for health care professionals. Dr. Di Bisceglie added, "We still believe there are other agents and treatment regimens that pose similar risks of HBV reactivation, and AASLD will call for further study and awareness of this and other agents may perhaps need similar box warnings."

Please follow this link for the FDA press release and additional information on HBV reactivation: http://www.fda.gov/Drugs/DrugSafety/ucm366406.htm.

 

AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists and has grown to an international society responsible for all aspects of hepatology.

Press releases and additional information about AASLD are available online at www.aasld.org.

Media Contact: Gregory Bologna
703/299-9766
gbologna@aasld.org

 

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.


'/>"/>
SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence, Even if Not Related to Safety
2. Physician-Patient Alliance for Health & Safety: Addressing The Joint Commission Opioid Warnings Can Reduce Respiratory Depression and Improve Patient Safety in Hospitals
3. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
4. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
5. Bulgaria Launches Development of National Hepatitis Plan
6. Major Breakthrough in Hepatitis C Vaccine Development
7. Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. Aethlon Medical Receives Intent to Issue Notice on European Patent to Remove Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Other Viral Pathogens From Blood
10. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
11. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016 /PRNewswire/--  Cell Applications, ... that advanced tissue-engineering services are now available in ... groundbreaking new three-dimensional (3D) bioprinting approach called the ... Bio Printer , a state-of-the-art robotic system that ... created a powerful pay-for-service bio-printing model that makes ...
(Date:2/8/2016)... , Feb. 8, 2016 Velano Vascular, ... experience for hospitalized patients and their practitioners, announced today ... in funding. Velano will use the proceeds from this ... financing completed in January 2015, to support the development ... adult and pediatric populations. Philadelphia ...
(Date:2/8/2016)... Corporation ("Unilife" or "Company") (NASDAQ: UNIS ; ASX: UNS), ... announced that it will release its financial results for the ... close on February 9, 2016.  At this time, the Company ... results.    About Unilife Corporation --> ... Unilife Corporation UNIS / ASX: UNS) ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced expansion into Canada to provide its range of unique and advantaged ... in Quebec City that will provide bilingual customer service and marketing support. A ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... program serving the greater Venice, FL area, has initiated a fundraiser for a ... car accident just four days after Christmas. To support this beautiful child who ...
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should try ... Clay” the health benefits of integrating clay into a daily diet are numerous, as ... motivational speaker, Perry A~ has since dedicated her life to learning about the benefits ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s ... booths and 700 companies. Attendees also get to see the most incredible gardens ... & Home Show , at the Colorado Convention Center - 700 14th St. Denver ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com recently ... in Mole removal products. , Moles are derived from a cluster of melanin when ... all the wrong places and create a lifetime of embarrassment. Historically, mole removal ...
Breaking Medicine News(10 mins):